centrosomal protein 250Genealiases: C-NAP1 · CEP2 · CNAP1 · CRDHL2
Q-omics provides the consensus-scored CEP250 profile across patient tissues and cancer cell-line models. CEP250 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CEP250 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CEP250 protein abundance shows 36,040 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight MESO, HNSC, and LUAD as cancer lineages where CEP250 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP250 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP250 survival associations across molecular data types. CEP250 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP250 RNA expression–survival associations across cancer types. High CEP250 expression shows unfavorable associations in MESO, LIHC, KICH, KIRP and THCA, but favorable associations in UCEC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CEP250 RNA expression.
This table summarizes CEP250 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CEP250. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP250 shows higher tumor expression in HNSC, KIRP, KIRC, COAD, LIHC and LUAD. The HNSC box plot shows higher CEP250 RNA expression in tumor versus normal tissue (log2 FC = +1.100, t-test p < 0.001).
This table shows molecular features associated with CEP250 in patient tissues and cancer cell lines. In patient samples, CEP250 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP250 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
